Amneal Pharmaceuticals Get Rating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Amneal pharmaceuticals get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Amneal Pharmaceuticals Get Rating Today - Breaking & Trending Today

Amneal Pharmaceuticals (NASDAQ:AMRX) Upgraded to Buy by StockNews.com

StockNews.com upgraded shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Friday. NASDAQ:AMRX opened at $3.19 on Friday. The stock has a market capitalization of $966.31 million, a price-to-earnings ratio of 159.50, a PEG ratio of 0.16 and a beta […] ....

Amneal Pharmaceuticals , Amneal Pharmaceuticals Get Rating , Amneal Pharmaceuticals Inc , Get Rating , Nasdaq Amrx , Stocknews Com ,

Amneal Pharmaceuticals (NYSE:AMRX) Downgraded by Zacks Investment Research to Sell

Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. […] ....

United States , New Jersey , Amneal Pharmaceuticals , Running Point Capital Advisors , Harel Insurance Investments Financial Services Ltd , Zacks Investment Research , Impax Laboratories Inc , Amneal Pharmaceuticals Inc , Lazard Asset Management , Amneal Pharmaceuticals Get Rating , Covestor Ltd , First Quadrant , Get Rating , North America , Insurance Investments , Financial Services , Point Capital Advisors , Asset Management , Nyse Amrx ,

Amneal Pharmaceuticals (NYSE:AMRX) Upgraded by Zacks Investment Research to "Hold"

Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports. According to Zacks, “Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company […] ....

United States , New Jersey , Amneal Pharmaceuticals , Zacks Investment Research , Nuveen Asset Management , Blackrock Inc , Impax Laboratories Inc , Amneal Pharmaceuticals Inc , Vanguard Group Inc , Amneal Pharmaceuticals Get Rating , Get Rating , North America , Asset Management , Nyse Amrx ,

Zacks: Analysts Expect Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Will Post Quarterly Sales of $534.46 Million

Wall Street brokerages expect that Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) will announce sales of $534.46 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Amneal Pharmaceuticals’ earnings. The lowest sales estimate is $528.92 million and the highest is $544.80 million. Amneal Pharmaceuticals posted sales of $535.08 million […] ....

Allspring Global Investments Holdings , Amneal Pharmaceuticals , Hedges Asset Management , Harel Insurance Investments Financial Services Ltd , Goldman Sachs Group Inc , Zacks Investment Research , Amneal Pharmaceuticals Inc , Amneal Pharmaceuticals Get Rating , Wall Street , Get Rating , Amneal Pharmaceutical , Investment Research , Global Investments Holdings , Insurance Investments , Financial Services , Asset Management , Goldman Sachs Group , Sachs Group , Nyse Amrx ,

$0.19 EPS Expected for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) This Quarter

Equities analysts forecast that Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Rating) will post earnings per share (EPS) of $0.19 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Amneal Pharmaceuticals’ earnings. The lowest EPS estimate is $0.18 and the highest is $0.21. Amneal Pharmaceuticals reported earnings per share of […] ....

Amneal Pharmaceuticals , Amneal Pharmaceuticals Get Rating , Zacks Investment Research , Amneal Pharmaceuticals Inc , Get Rating , Amneal Pharmaceutical , Nasdaq Amrx ,